Literature DB >> 33297927

Molecular Evaluation of MicroRNA-146 Gene Variability (rs2910164 C> G) and its Association with Increased Susceptibility to Coronary Artery Disease.

Rashid Mir1, Imadeldin Elfaki2, Chandan Jha3, Jamsheed Javid1, Suriya Rehman4, Shaheena Banu5, Mohammad Muzaffar Mir6, Abdullatif Taha Babakr7, Sukh Mohinder Singh Chahal2.   

Abstract

AIM: Apart from the modifiable risk factors, genetic factors are believed to influence the outcome of Coronary Artery Diseases (CAD). Under the genetic factors, miRNA polymorphisms, namely Hsa-miR-146a-5p (rs2910164) have become an important tool to study the mechanism that underlies the pathogenesis of this disease. Therefore, we investigated the association of miR-146a gene variations with susceptibility of coronary artery diseases.
METHODOLOGY: This study was conducted on 100 CAD patients and 117 matched healthy individuals. Genotyping of the Hsa-miR-146a-5p C>G gene variation was performed by using Amplification Refractory Mutation System PCR method (ARMS-PCR).
RESULTS: The distribution of Hsa-miR-146a-5p rs2910164 C>G genotypes observed between patients and controls was significantly different (P=0.048). Moreover, the frequency of G allele (fG) was found to be significantly higher among patients than in controls (0.36 vs. 0.25). Our findings showed that the Hsa-miR-146a-5p C>G variant was associated with an increased risk of CAD in codominant inheritance model CC vs. CG genotype (OR = 1.84, 95% CI, 1.02-3.31; p=0.040) and (OR = 3.18, 95% CI, 1.02-9.9; p=0.045) for CC vs. GG genotype in dominant inheritance model. Whereas the G allele significantly increased the risk of coronary artery disease (OR =1,81, 95% CI, 1.18-2.78; p=0.006) compared to C allele. Taken together, these results demonstrated that miR-146a/rs2910164 is associated with susceptibility to coronary artery disease, providing novel insights into the genetic etiology and underlying biology of coronary artery disease.
CONCLUSION: Our findings indicated that Hsa-miR-146a-5p rs2910164 GG genotype and G allele are associated with increased susceptibility to Coronary Artery Disease. A larger sample size can be the key to progress in establishing the genetic co-relation of miRNA gene polymorphisms and cardiovascular diseases. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Coronary Artery Disease (CAD); Hsa-miR-146a-5p; amplification refractoryzzm321990mutation system (ARMS-PCR); gene polymorphism; miRNA polymorphisms; microRNAs

Year:  2020        PMID: 33297927     DOI: 10.2174/2211536609666201209151130

Source DB:  PubMed          Journal:  Microrna


  3 in total

1.  Molecular Determination of Vascular Endothelial Growth Factor, miRNA-423 Gene Abnormalities by Utilizing ARMS-PCR and Their Association with Fetal Hemoglobin Expression in the Patients with Sickle Cell Disease.

Authors:  Abdullah Hamadi; Rashid Mir; Ali Mahzari; Abdulrahim Hakami; Reema Almotairi; Gasim Dobie; Fawaz Hamdi; Mohammed Hassan Nahari; Razan Alhefzi; Mohammed Alasseiri; Nora Y Hakami; Hadeel Al Sadoun; Osama M Al-Amer; Jameel Barnawi; Hassan A Madkhali
Journal:  Curr Issues Mol Biol       Date:  2022-06-01       Impact factor: 2.976

2.  Genetic Variants of MIR27A, MIR196A2 May Impact the Risk for the Onset of Coronary Artery Disease in the Pakistani Population.

Authors:  Taqweem Ul Haq; Abdul Zahoor; Yasir Ali; Yangchao Chen; Fazal Jalil; Aftab Ali Shah
Journal:  Genes (Basel)       Date:  2022-04-24       Impact factor: 4.141

3.  Biochemical Characterization and Molecular Determination of Estrogen Receptor-α (ESR1 PvuII-rs2234693 T>C) and MiRNA-146a (rs2910164 C>G) Polymorphic Gene Variations and Their Association with the Risk of Polycystic Ovary Syndrome.

Authors:  Rashid Mir; Faris J Tayeb; Jameel Barnawi; Mohammed M Jalal; Nizar H Saeedi; Abdullah Hamadi; Malik A Altayar; Sanad E Alshammari; Nabil Mtiraoui; Mohammed Eltigani Ali; Faisel M Abu Duhier; Mohammad Fahad Ullah
Journal:  Int J Environ Res Public Health       Date:  2022-03-06       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.